<DOC>
	<DOCNO>NCT00646139</DOCNO>
	<brief_summary>RATIONALE : KX2-391 may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose KX2-391 treating patient advance solid tumor lymphoma respond treatment .</brief_summary>
	<brief_title>KX2-391 Treating Patients With Advanced Solid Tumors Lymphoma That Did Not Respond Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - To define maximum tolerate dose KX2-391 administer multiple oral solution patient refractory advanced solid tumor lymphoma . Secondary - To determine safety tolerability KX2-391 give single multiple oral solution patient . - To characterize pharmacokinetic profile single dose multiple dose KX2-391 patient . - To determine biological effect KX2-391 . OUTLINE : This multicenter study . Patients receive oral KX2-391 twice daily 3 week . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Blood urine sample collect periodically pharmacokinetic study . Biological effect assess measure plasma level vascular endothelial growth factor ELISA . Levels phospho-Src Tyr transphosphorylation select substrate measure peripheral blood mononuclear cell .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis advance solid tumor lymphoma Metastatic unresectable disease Standard curative palliative measure exist longer effective Patients treat brain ocular metastasis eligible PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 14 week ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Serum bilirubin ≤ 2.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Serum creatinine ≤ 1.5 time ULN creatinine clearance &gt; 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 1 month prior , , 6 month completion study treatment No inflammatory bowel disease , malabsorption syndrome , medical condition may interfere oral drug absorption No sign symptom end organ failure , major chronic illness cancer , severe concomitant condition include , limited , active infection , opinion investigator , preclude protocol participation compliance No history follow within past 6 month : Angina pectoris Coronary artery disease Hypertension Cerebral vascular accident Transient ischemic attack uncontrolled medical therapy No history confirm cardiac conduction abnormality arrhythmias No known history hepatitis B C , HIV infection No known history coagulation disorder hemolytic condition ( e.g. , sickle cell anemia ) PRIOR CONCURRENT THERAPY : Recovered prior therapy No prior major surgery upper gastrointestinal tract More 2 week since prior investigational agent systemic anticancer agent ( 28 day agent unknown elimination halflives know elimination halflives &gt; 50 hour ) More 4 week since prior radiotherapy sternum , pelvis , scapula , vertebra , skull recover More 4 week since prior major surgery More 1 week since prior palliative lowdose radiotherapy limb recover More 2 week since prior concurrent hormone ( e.g. , estrogen contraceptive , hormone replacement , antiestrogen , progesterone ) antiplatelet agent More 2 week since prior concurrent anticoagulant ( e.g. , coumadin ) except prophylactic dos anticoagulant indwell venous catheter More 2 week 5 halflives since prior concurrent cytochrome P450 modulators ( e.g. , strong inducer inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>small intestine lymphoma</keyword>
</DOC>